Xie C - Search Results

1

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy.

Wang K, Zhang Y, Su Z, Wang B, Zhou Y, Tong X, Xie C, Luo X, Zhang S, Zheng M. Wang K, et al. Among authors: xie c. Cancer Med. 2025 Jan;14(1):e70556. doi: 10.1002/cam4.70556. Cancer Med. 2025. PMID: 39791593 Free PMC article.

2

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.

Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Xie C, et al. Cancer Sci. 2018 Apr;109(4):1207-1219. doi: 10.1111/cas.13536. Epub 2018 Mar 25. Cancer Sci. 2018. PMID: 29446853 Free PMC article.

3

BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.

Yao MY, Wang YF, Zhao Y, Ling LJ, He Y, Wen J, Zheng MY, Jiang HL, Xie CY. Yao MY, et al. Am J Cancer Res. 2022 Aug 15;12(8):3829-3842. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119822 Free PMC article.

4

Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.

Xie C, Chen X, Zheng M, Liu X, Wang H, Lou L. Xie C, et al. Oncotarget. 2017 Nov 14;8(64):107977-107990. doi: 10.18632/oncotarget.22439. eCollection 2017 Dec 8. Oncotarget. 2017. PMID: 29296217 Free PMC article.

5

143D, a novel selective KRAS^G12C inhibitor exhibits potent antitumor activity in preclinical models.

Xu LS, Zheng SX, Mei LH, Yang KX, Wang YF, Zhou Q, Kong XT, Zheng MY, Jiang HL, Xie CY. Xu LS, et al. Acta Pharmacol Sin. 2023 Jul;44(7):1475-1486. doi: 10.1038/s41401-023-01053-2. Epub 2023 Feb 1. Acta Pharmacol Sin. 2023. PMID: 36725884 Free PMC article.

6

Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.

Wang W, Liu Y, Zhao Z, Xie C, Xu Y, Hu Y, Quan H, Lou L. Wang W, et al. Among authors: xie c. Cancer Sci. 2016 Jun;107(6):782-90. doi: 10.1111/cas.12934. Epub 2016 Apr 27. Cancer Sci. 2016. PMID: 27002306 Free PMC article.

7

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.

Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, Sun R, Jia Y, Wang Y, Shen J, Wang D, Wang S, Jiang H, Jiang B, Yang X, Xie C. Luo Z, et al. Among authors: xie c. Cancer Res. 2025 Jan 2;85(1):101-117. doi: 10.1158/0008-5472.CAN-24-1093. Cancer Res. 2025. PMID: 39437162 Free PMC article.

8

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.

Long F, He Y, Fu H, Li Y, Bao X, Wang Q, Wang Y, Xie C, Lou L. Long F, et al. Among authors: xie c. Cancer Sci. 2019 Apr;110(4):1420-1430. doi: 10.1111/cas.13957. Epub 2019 Feb 26. Cancer Sci. 2019. PMID: 30724426 Free PMC article.

9

X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.

Zhao Z, Zhu J, Quan H, Wang G, Li B, Zhu W, Xie C, Lou L. Zhao Z, et al. Among authors: xie c. Oncotarget. 2016 May 17;7(20):29648-63. doi: 10.18632/oncotarget.8818. Oncotarget. 2016. PMID: 27105490 Free PMC article.

10

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.

Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. Xie C, et al. Cancer Sci. 2017 Jul;108(7):1476-1484. doi: 10.1111/cas.13263. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28418085 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,382 results

Search Page

Filters